Purpose The purpose of this study was to assess, in a large sample of healthy young adults, sex differences in the binding potential of [ 
Introduction
ABP688 (3-((6-methylpyridin-2-yl)ethynyl)cyclo-hex-2-en-1-one-O-methyloxime) is a selective allosteric ligand of the metabotropic glutamate type 5 (mGlu5) receptor. Positron emission tomography (PET) studies with 11 C labeled ABP688 have identified replicable group differences [1] [2] [3] [4] , but variability in the tracer's binding in humans has proven to be unexpectedly high [5, 6] . Some sources of variability have been identified, including circadian changes in receptor availability [6, 7] and tracer (E)-isomer content [8] . However, variability remains high when these factors are accounted for [5, 8] , suggesting that further sources remain unknown.
One potential source of variability is biological sex. Lower PET [ more recent comparison [9] . In clinical populations, the majority of scans have been conducted in men, but some evidence has emerged of sex-specific disease effects. In people with schizophrenia, regional [ 11 C]ABP688 BP ND was higher in female patients but lower in male patients relative to sexmatched healthy controls [10] . Pre-clinical and post-mortem research also suggests that sex differences exist in the role of mGlu5 receptors in substance use disorders, depression, and responses to stress [11] [12] [13] [14] .
Given the high variability in tracer binding measures, the relatively small sample sizes in previous studies coupled with the possibility of menstrual-cycle associated changes might have limited the ability to detect sex differences. Thus, the current study's objective was to assess sex differences in [ 11 C]ABP688 BP ND in a large sample of healthy young adults.
Methods
Seventy-four healthy volunteers were included in this study (25 men and 49 women, mean age 20 ± 3.0 years). Five participants were current cigarette smokers (4 women, 1 man); none of the participants had any Axis I psychiatric disorders. Participants were recruited from community advertisements (n = 25) or from one of three longitudinal cohorts (Quebec Study of Newborn Twins, n = 5, and two cohorts from the Quebec Longitudinal Study of Child Development, n = 44). In the case of twins, only a single volunteer per twin pair was included. The study was carried out in accordance with the Declaration of Helsinki and approved by the Research Ethics Board of the Montreal Neurological Institute, McGill University, the ethics committee of the CHU Sainte-Justine Research Center, and the ethics committe of the Institut de la Statistique du Quebec. All participants provided written informed consent.
For female participants, menstrual phase at the time of the scan was determined based on the date of last menstrual period and length of cycle (self-report). Serum levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were measured in a subset of participants (n = 10) to confirm this. Of women not using hormonal contraception (n = 29), the majority (n = 21) were tested during the follicular phase, five during the luteal phase, and three during ovulation.
PET scans were acquired between 10 am and 3 pm using a high-resolution research tomograph (HRRT, CTI/Siemens). Prior to injection of the ligand, a 6-min transmission scan was performed with 137 Cs to correct for tissue attenuation. Subsequently, a 60-min dynamic scan was initiated concurrent with the beginning of a one-minute bolus injection of 370 MBq [ 11 C]ABP688. Dynamic data were collected with the scanner in list mode and reconstructed using an ordered subset maximization algorithm including motion correction to the transmission scan. High-resolution (1 mm 3 ) T1-weighted anatomical magnetic resonance imaging (MRI) scans were acquired using a 1.5 T Siemens Sonata scanner (gradient echo pulse sequence, repetition time = 9.7 ms, echo time = 4 ms, flip angle = 12°, field of view = 250 mm and matrix = 256 × 256) or a 3 T Siemens Trio TIM scanner (MPRAGE sequence, repetition time = 2300 ms, echo time = 3.42 ms, flip angle = 9°, field of view = 256 mm and matrix = 256 × 256).
Regions of interest (ROIs) were defined using standard masks on the MNI152 template then registered to individual PET images. The ROIs included three prefrontal cortex subregions (orbitofrontal, dorsolateral, and medial), three functional striatum subregions (associative, sensorimotor and ventral), insula, hippocampus, and amygdala. Regional nondisplaceable binding potential values (BP ND ) were extracted from each ROI using the simplified reference tissue model with cerebellar grey matter as the reference tissue. Scan start times were compared between men and women using independent samples t tests. Percent (E)-isomer content and injected tracer mass were compared using the Wilcoxon rank sum test due to their non-normal distribution. The effect of sex on BP ND values was analyzed using repeated measures analysis of covariance (ANCOVA) with region as a repeated measure, sex as a between subject factor, and tracer (Z)-isomer content and smoking status as covariates. Post-hoc independent samples t-tests were then performed within each ROI. Whole brain voxel-wise analyses of BP ND were compared 
Results
Sample and PET scan characteristics are summarized in Table 1 . Scans performed on men and women did not differ in start time (t = −0.001, p = 1.0) or % (E)-isomer in tracer batch (Wilcoxon rank sum test W = 708, p = 0.28). Tracer injected mass was higher in scans performed on women than men (W = 437, p = 0.045). Injected mass was not correlated with BP ND in any region (ps > 0.06, uncorrected) and was therefore not included in subsequent analyses [15] .
In the ROI analysis of BP ND , the ANCOVA yielded main effects of sex (F 1,68 = 12.8, p = 0.001) and region (F 8,544 = 3.6, p < 0.001) and a sex × region interaction (F 8,624 = 6.0, p < 0.001). In post hoc comparisons of each ROI, BP ND was significantly higher in men compared to women in all regions (ps < 0.042) apart from the amygdala (p = 0.062) ( Table 2) .
Comparison of the magnitude of sex differences in each region suggests that the sex × region interaction emerges from greater difference between sexes in prefrontal cortex subregions than in subcortical limbic structures. The largest magnitude of difference was in the orbitofrontal cortex where mean BP ND was 22% greater in men compared to women, and the smallest in the amygdala, where BP ND was 11% higher in men. Voxel-wise analyses were consistent with these findings, with clusters of higher BP ND in men emerging in the prefrontal cortex, striatum, and insula ( Fig. 1) , as well as in the temporal, parietal, and occipital cortices (cluster-level ps < 0.05, familywise-error-corrected).
In women, BP ND values did not differ across menstrual phase groups (ps > 0.05 in each region) (Fig. 2) . BP ND was not statistically related to LH (r = −0.33, p = 0.35) or FSH (r = −0.043, p = 0.91) levels in a subset of ten women.
Discussion
In this pooled analysis of healthy young adults comprising the largest sample reported to date, brain [ 11 C]ABP688 BP ND values were significantly higher in men compared to women. These results are in agreement with a previous study finding lower [ 11 C]ABP688 BP ND in female nonsmokers compared to male nonsmokers [1] . In comparison, several studies with an even sex split or greater numbers of female participants found no effect of sex on tracer binding [2, 9, 16] . Given the high variability in [ 11 C]ABP688 binding estimates, sex differences may have been masked in previous studies with smaller sample sizes.
The observed sex differences might reflect an influence of gonadal hormones. Estrogen receptors are functionally coupled to mGlu5 receptors in striatal medium spiny neurons, and treatment with a negative allosteric modulator for mGlu5 abolishes estradiol enhancement of stimulant sensitization [12, 17] . The present work suggests that sex differences are present in healthy humans and can be identified using PET [ 11 C]ABP688 imaging. Future studies should account for these differences both as a possible source of variability in binding measures and as a biological factor potentially contributing to sex differences in neurocognitive function and neuropsychiatric disorders.
